BioTalk is a news hub brought to you by Bird & Bird's International Life Sciences & Healthcare Group. Read more about us >

Transfer of value in France: the long-awaited “anti-gift” decree has finally been published

Healthcare 2 min
June 19, 2020

The French so-called “anti-gift” provisions strictly frame the conditions under which companies in the health sector are allowed to provide advantages, in cash or in kind, to healthcare professionals (“HCPs”).

The “anti-gift” regime was significantly amended in 2017 but the application of the new provisions remained subject to implementing texts whose publication has been awaited since then.

The decree relating to the advantages granted by persons manufacturing or marketing health products or services was finally published on 17 June 2020.

It will enter into force on 1 October 2020. This leaves about 3 months for companies to implement new compliance procedures.

An important change as compared to the current regime is that the submission procedure will depend on the value of the advantage in question:

  • a declaration procedure for advantages under the ceilings set by an arrêté – yet to be published: 
    • the submission will have to be filed with the competent authority (the CNOM for physicians) 8 days before the grant of the advantage
    • the competent authority will have the possibility to make recommendations
  • an authorization procedure for advantages above said ceilings: 
    • the whole procedure may take up to 4 months, meaning that to be on the safe side companies would have to file their submissions at least 4 months before the contemplated event or service,
    • the competent authority (the CNOM for physicians) will have 2 months to give a decision, or longer in cases where the authority notifies the applicant that the submitted file was incomplete; in case of refusal, the applicant can submit an amended submission within 15 days and the competent authority will issue a new decision in 15 days,
    • the decision issued by the competent authority will be binding, meaning that the transfer of value cannot take place in the absence of an implicit (ie. no reply within the set time frame) or explicit approval.

Although the texts setting the ceilings under which the declaration procedure will apply have not yet been published, said ceilings are likely to be lower than the currently accepted one for hospitality and payment for services.

The decree also specifies the mandatory contents of the submission including the contract framing the transfer of value. It should be noted that in cases where the beneficiary HCP is a public agent (employed by a public hospital or university), an authorization by his hierarchy will have to be included in the submission.

Written by
Alexandre Vuchot
Alexandre Vuchot
I'm a partner in Bird & Bird's international Commercial group, based in Paris, where I provide our clients with strategic commercial advice. With both French and English qualifications in commercial and corporate law, I have extensive experience of transactional matters. I am able to offer comprehensive advice on all aspects of general business law. I assist on commercial contracts covering distribution, franchise, sales, agency, cooperation and procurement arrangements, acting for suppliers and customers particularly in the retail, tech & comms, life sciences, as well as gaming, entertainment and sport sectors.
Dora Talvard
Dora Talvard
My work is focused on the life sciences and healthcare sectors. I advise clients on a broad range of regulatory aspects. I work hand in hand with the intellectual property, data protection, commercial and corporate lawyers of the firm to provide clients with tailor made advice and solutions.

Related articles

Dutch competition authority ACM publishes a sector report on the impact of biosimilars on competition between TNF-alfa inhibitors
The Dutch competition authority, ACM, initiated a market study in 2018 into the effect of the introduction...
COVID-19: The NIPN’s Regulatory and Data Protection Guidance on adjustments in clinical trials
On the tails of the EMA’s Guidance on the Management of Clinical Trials during the COVID-19 pandemic,...